The evaluation of Anti-Müllerian Hormone (AMH) levels plays a crucial role in optimizing prime pathways for In Vitro Fertilization (IVF). AMH Test, a hormone produced by ovarian follicles, serves as a reliable indicator of ovarian reserve, reflecting the quantity and quality of a woman's remaining eggs. By assessing a patient's AMH levels, fertility specialists can tailor IVF treatment plans to maximize chances of success. Optimizing prime IVF pathways involves utilizing AMH data to determine appropriate medication dosages, timing of procedures, and overall treatment strategies tailored to individual patient needs. This personalized approach enhances the efficiency and effectiveness of Prime IVF protocols, leading to improved outcomes and higher success rates.